Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Upcoming treatments for bladder cancer

Arlene Siefker-Radtke • 3 Jun 2019
ASCO 2019
Bladder Cancer Enfortumab vedotin

Arlene Siefker-Radtke, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses upcoming treatments for bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:21
Genomic differences between urachal and non-urachal bladder adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:09
What role does FDG-PET have in managing bladder cancer?
Antonio Cigliola • 26 Jan 2024
1:06
Predicting pelvic lymph node involvement in MIBC with FDG-PET
Antonio Cigliola • 26 Jan 2024
The content of VJOncology is intended for healthcare professionals